TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21216475

Group type: EXPERIMENTAL
Intervention: SSRI Citalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various medications administered in level 3
Number of subjects: 0
Study: 21216880

Group type: EXPERIMENTAL
Intervention: Serum PARC/CCL-18 levels in COPD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated PARC/CCL-18 levels
Number of subjects: 0
Study: 21217080

Group type: EXPERIMENTAL
Intervention: Pitted cell counts (PIT)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Quantitative Howell-Jolly bodies (HJB)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Liver-spleen scan
Number of subjects: 193
Study: 21217520

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy
Number of subjects: 60
Study: 21219411

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous sildenafil bolus
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg oral sildenafil tablet
Number of subjects: 0
Study: 21219434

Group type: EXPERIMENTAL
Intervention: Always used injection-meal interval (Type 1 diabetes); n=39, age 58 years, duration of diabetes 21.1 years, BMI 28.7 kg/m², HbA(1c) 7.50%/58 mmol/mol
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Always used injection-meal interval (Type 2 diabetes); n=124, age 65 years, duration of diabetes 13.8 years, BMI 32.6 kg/m², HbA(1c) 7.31%/56 mmol/mol
Number of subjects: 433
Study: 21220472

Group type: EXPERIMENTAL
Intervention: CBP501 alone (0.9 mg/m(2), D1/D8/D15, q4w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBP501 in combination with cisplatin (3.6 mg/m(2) CBP501, 50 mg/m(2) cisplatin, both on D1, q3w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBP501/cisplatin combination
Number of subjects: 0
Study: 21220675

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs) and memantine hydrochloride
Number of subjects: 590

Group type: COMPARATOR
Intervention: Cholinesterase inhibitors (ChEIs) only
Number of subjects: 590
Study: 21220996

Group type: EXPERIMENTAL
Intervention: sRAGE levels in patients with acute lung injury/acute respiratory distress syndrome (n=15)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: sRAGE levels in patients with acute lung injury/acute respiratory distress syndrome plus severe sepsis/septic shock (n=18)
Number of subjects: 64

Group type: COMPARATOR
Intervention: sRAGE levels in patients with severe sepsis/septic shock (n=16)
Number of subjects: 64

Group type: COMPARATOR
Intervention: sRAGE levels in mechanically ventilated controls (n=15)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Correlation of sRAGE levels with acute lung injury/acute respiratory distress syndrome severity
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: sRAGE levels over time
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lower baseline plasma sRAGE
Number of subjects: 64
Study: 21222188

Group type: EXPERIMENTAL
Intervention: Delirium assessment using the Confusion Assessment Method on postoperative days two, four, and discharge.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Neuropsychometric testing at discharge and three months following surgery.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis to evaluate predictors of delirium and POCD.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E-ε4 genotype assessment.
Number of subjects: 88
Study: 21224253

Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight management program
Number of subjects: 67
Study: 21224368

Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203) 2 mg/kg i.v. weekly (qw) or biweekly (q2w)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203) 0.1 to 3.0 mg/kg i.v. qw or q2w
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203) 3.0 mg/kg i.v. qw or q2w
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CT-322 (BMS-844203)
Number of subjects: 39
Study: 21225123

Group type: EXPERIMENTAL
Intervention: Stratus-OCT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 40
Study: 21226540

Group type: EXPERIMENTAL
Intervention: Omega-3 index < 4.0 (high risk) in obese children (BMI z-score > 2.25)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher omega-3 index (6.0-8.0 lower risk) in non-obese children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between omega-3 index and fasting insulin level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between omega-3 index and HOMA scores
Number of subjects: 0
Study: 21226927

Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose, followed by 75 mg daily)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg loading dose, followed by 100 mg daily)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Ticlopidine or prasugrel (if available and not contraindicated)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Structured therapy plan based on a 'test and treat' strategy
Number of subjects: 504
Study: 21227674

Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 4635

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4635

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 4635

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 4635

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 4635
Study: 21228328

Group type: COMPARATOR
Intervention: melphalan-prednisone alone (n = 332)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-thalidomide (n = 332)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-bortezomib (n = 257)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone-bortezomib-thalidomide (n = 254)
Number of subjects: 1175
Study: 21229597

Group type: EXPERIMENTAL
Intervention: Telephone Interview for Cognitive Status (TICS) screening
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: TICS scores
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: TICS
Number of subjects: 343
Study: 21232152

Group type: EXPERIMENTAL
Intervention: High nicotine dependence (FTND score)
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Lower FTND score, male gender, lower body mass index, and lower FEV1
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Genetic variants in CHRNA3/5
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Nicotine dependence
Number of subjects: 842
Study: 21232715

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1302
Study: 21232716

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 4692
Study: 21232717

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2738

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2738
Study: 21232745

Group type: EXPERIMENTAL
Intervention: MMP-1 G insertion
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MMP-9≥22 repeats
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Persistent angina and NSTEMI
Number of subjects: 204
Study: 21233271

Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) lower dose (4, 4 and 8 mg·kg(-1))
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) higher dose (10, 10 and 20 mg·kg(-1))
Number of subjects: 19
Study: 21233705

Group type: EXPERIMENTAL
Intervention: DIEP flap perfusion measured by laser Doppler imager
Number of subjects: 14
Study: 21234288

Group type: EXPERIMENTAL
Intervention: Breast health supplement containing HMR lignan, indole-3-carbinol, calcium glucarate, milk thistle, Schisandra chinesis and stinging nettle for 28 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 96
Study: 21236414

Group type: EXPERIMENTAL
Intervention: Under-corrected spectacles up to -1.5 D
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Maximal tolerable amount of under-correction (mean -0.89 D)
Number of subjects: 38
Study: 21239695

Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m² days 1 and 4; Rituximab 375 mg/m² day 1; Bortezomib 1.3 mg/m² days 1, 4, 8, 11 (6 cycles of 28 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bendamustine, Bortezomib, and Rituximab combination
Number of subjects: 30
Study: 21239698

Group type: EXPERIMENTAL
Intervention: Flavopiridol (30-mg/m(2) bolus, 60-mg/m(2) infusion)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Flavopiridol (30-mg/m(2) bolus, 70-mg/m(2) infusion)
Number of subjects: 55
Study: 21241171

Group type: EXPERIMENTAL
Intervention: Urban underserved group
Number of subjects: 1514

Group type: COMPARATOR
Intervention: Rural underserved group
Number of subjects: 1514
Study: 21242187

Group type: EXPERIMENTAL
Intervention: Re-induction therapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Presence of FLT3-internal tandem duplication
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Age above the median of 47 years
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: None of the negative prognostic factors (FLT3-internal tandem duplication, age above median)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: One negative prognostic factor (FLT3-internal tandem duplication or age above median)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both negative prognostic factors (FLT3-internal tandem duplication and age above median)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation after relapse
Number of subjects: 94
Study: 21242491

Group type: EXPERIMENTAL
Intervention: Tandutinib 500 mg twice daily
Number of subjects: 6
Study: 21242992

Group type: EXPERIMENTAL
Intervention: Sertraline (open-label treatment for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (18 individuals)
Number of subjects: 38
Study: 21244307

Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (PR), maximum 24 mg/day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ropinirole prolonged release (PR)
Number of subjects: 83
Study: 21245420

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab with chemotherapy
Number of subjects: 799
Study: 21245726

Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at baseline
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: NT-proBNP (highest vs lowest quartile)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: NT-proBNP (after adjustment for covariates)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: NT-proBNP (after additional adjustment for IL-6, high-sensitivity C-reactive protein, and D-dimer)
Number of subjects: 515
Study: 21245868

Group type: EXPERIMENTAL
Intervention: Bevacizumab with therapeutic anticoagulation (TA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo with therapeutic anticoagulation (TA)
Number of subjects: 3
Study: 21247312

Group type: EXPERIMENTAL
Intervention: Mutations in genes associated with idiopathic hypogonadotropic hypogonadism in women with hypothalamic amenorrhea (FGFR1, PROKR2, GNRHR, KAL1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: In vitro studies of identified mutations
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group with normal menstrual cycles
Number of subjects: 55
Study: 21247313

Group type: EXPERIMENTAL
Intervention: Culprit lesions
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with plaque burden of 70% or greater
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with minimal luminal area of 4.0 mm² or less
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Nonculprit lesions classified as thin-cap fibroatheromas
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Overall major adverse cardiovascular events
Number of subjects: 697
Study: 21248153

Group type: EXPERIMENTAL
Intervention: Injection drug users (IDUs)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Nonaddicts
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: SAB
Number of subjects: 87
Study: 21249218

Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium nitrite infusion at maximal tolerated dose
Number of subjects: 12
Study: 21251599

Group type: EXPERIMENTAL
Intervention: Memory training intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Health training control
Number of subjects: 22
Study: 21251631

Group type: EXPERIMENTAL
Intervention: SXscore tertile SX(HIGH) >16
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Combination SYNTAX-PAMI score
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: SXscore
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: PAMI score
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Combined SYNTAX-PAMI score
Number of subjects: 807
Study: 21251673

Group type: EXPERIMENTAL
Intervention: 10 mg alfuzosin XL for 12 months
Number of subjects: 108
Study: 21252039

Group type: EXPERIMENTAL
Intervention: Cognitive abilities assessed using Free and Cued Selective Recall Reminding Test (FCSRT)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Cognitive abilities assessed using Benton visual retention test
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Cognitive abilities assessed using similarities subtest of the Wechsler Adult Intelligence Scale-Revised
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Anxiety and cognitive complaints measured at baseline
Number of subjects: 686
Study: 21252240

Group type: EXPERIMENTAL
Intervention: Incretin effect measured over 6 days with three 4-h oral glucose tolerance tests (25, 75, and 125 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral glucose tolerance tests with increasing glucose loads
Number of subjects: 8

Group type: COMPARATOR
Intervention: Incretin hormone responses
Number of subjects: 8
Study: 21252248

Group type: EXPERIMENTAL
Intervention: Untreated PCOS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 74
Study: 21253319

Group type: EXPERIMENTAL
Intervention: FOLFOX (adjuvant folinic acid/fluorouracil plus oxaliplatin)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Overall chemotherapy (FOLFOX and XELOX)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Age ≥55 years
Number of subjects: 366

Group type: COMPARATOR
Intervention: Stage II or III
Number of subjects: 366

Group type: COMPARATOR
Intervention: Adjuvant setting
Number of subjects: 366

Group type: COMPARATOR
Intervention: Performance status of 0
Number of subjects: 366

Group type: COMPARATOR
Intervention: No prior chemotherapy
Number of subjects: 366
Study: 21255443

Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic cardiac catheterization
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age and hypertension (risk factors)
Number of subjects: 300
Study: 21255766

Group type: EXPERIMENTAL
Intervention: Any antidepressant
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Guideline-level antidepressant dose and duration
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Any psychotherapy
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Guideline-level psychotherapy
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants and individual psychotherapy
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Mental health treatment
Number of subjects: 947
Study: 21256189

Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 combined with the adjuvant IC31(®), administered at 0 and 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 combined with the adjuvant IC31(®)
Number of subjects: 0
Study: 21262599

Group type: EXPERIMENTAL
Intervention: Cutaneous malignant melanomas (CMM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Benign melanocytic nevi (BMN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dysplastic melanocytic nevi (DMN)
Number of subjects: 30
Study: 21262916

Group type: EXPERIMENTAL
Intervention: Carboplatin/pemetrexed therapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Higher tertile of TS mRNA expression
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TS mRNA level and TS H-score
Number of subjects: 126

Group type: COMPARATOR
Intervention: ERCC1 protein expression, TS and ERCC1 polymorphisms
Number of subjects: 126
Study: 21262992

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 3670
Study: 21263104

Group type: EXPERIMENTAL
Intervention: Microalbuminuria
Number of subjects: 28384

Group type: EXPERIMENTAL
Intervention: Macroalbuminuria
Number of subjects: 28384

Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (microalbuminuria)
Number of subjects: 28384

Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (macroalbuminuria)
Number of subjects: 28384

Group type: EXPERIMENTAL
Intervention: New microalbuminuria
Number of subjects: 28384

Group type: EXPERIMENTAL
Intervention: New macroalbuminuria
Number of subjects: 28384

Group type: EXPERIMENTAL
Intervention: Baseline macroalbuminuria treated with ACE inhibitor/ARB
Number of subjects: 28384
Study: 21266211

Group type: EXPERIMENTAL
Intervention: POTS patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 21267044

Group type: EXPERIMENTAL
Intervention: 24-hour intravenous patient-controlled analgesia (IV-PCA) with oxymorphone
Number of subjects: 12
Study: 21267531

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with capecitabine (825 mg/m² twice a day on radiotherapy days; weeks 1-4) and oxaliplatin (50 mg/m² intravenously on days 1, 8, 15, and 22) with radiotherapy (total dose 45 Gy)
Number of subjects: 59
Study: 21267960

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors (88%)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Beta-blockers (77%)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Both converting enzyme inhibitors and beta-blockers (60%)
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Cardiovascular hospitalisation
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Unscheduled surgery visits
Number of subjects: 822
Study: 21269431

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Higher TSH levels
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: TSH, nulliparity, frank breech, placenta anterior
Number of subjects: 141
Study: 21269835

Group type: EXPERIMENTAL
Intervention: Single-limb support quintiles
Number of subjects: 125
Study: 21270268

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (L-NMMA)
Number of subjects: 84
Study: 21270271

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1116
Study: 21271599

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 17
Study: 21273144

Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting balloons (DEB) including SeQuent Please, In.Pact Falcon, New Dior, Pantera Lux
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting balloons (DEB)
Number of subjects: 14
Study: 21273196

Group type: EXPERIMENTAL
Intervention: Electronic repositioning
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard LVtip to LVring configuration
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Alternative configurations
Number of subjects: 228
Study: 21273493

Group type: EXPERIMENTAL
Intervention: Insulin lispro with rHuPH20
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Regular human insulin (RHI) with rHuPH20
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin lispro without rHuPH20
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular human insulin (RHI) without rHuPH20
Number of subjects: 22
Study: 21273497

Group type: EXPERIMENTAL
Intervention: Vietnamese American patients with clinical depression (CES-D score ≥ 22)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Mexican American patients with clinical depression (CES-D score ≥ 22)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Non-Hispanic white patients with clinical depression (CES-D score ≥ 22)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Vietnamese and Mexican patients with high depressive symptoms
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Minority patients with low levels of trust in their provider
Number of subjects: 1209
Study: 21273938

Group type: EXPERIMENTAL
Intervention: Trivalent, inactivated influenza vaccine (TIV), 2 doses
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (FT infants)
Number of subjects: 41
Study: 21274359

Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention (11 group sessions and weekly fitness training for 5 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 50
Study: 21274364

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patches (4.6 mg/24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Donepezil (5 to 10 mg/d)
Number of subjects: 0
Study: 21276128

Group type: EXPERIMENTAL
Intervention: PEM-guided biopsy
Number of subjects: 19
Study: 21276234

Group type: EXPERIMENTAL
Intervention: Intensity-modulated whole abdominal radiotherapy (WAR)
Number of subjects: 37
Study: 21277098

Group type: EXPERIMENTAL
Intervention: Thalidomide + Radiotherapy (RT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Radiotherapy (RT) only
Number of subjects: 24
Study: 21277691

Group type: EXPERIMENTAL
Intervention: High-energy focused extracorporeal shockwave therapy
Number of subjects: 566
Study: 21278138

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) with unblinded use after 4 weeks
Number of subjects: 60
Study: 21279689

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMRI)
Number of subjects: 20
Study: 21280008

Group type: EXPERIMENTAL
Intervention: MicroRNA expression profiles from patients with SS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time quantitative polymerase chain reaction validation of microRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MicroRNA from patients with preserved or low salivary flow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted biologic targets of microRNA associated with inflammation or salivary gland dysfunction
Number of subjects: 0